Immunitybio announces $157 million financing from nant and institutional investor

Culver city, calif.--( business wire )--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations.
IBRX Ratings Summary
IBRX Quant Ranking